Checking your passage…

Sources and review scope

These source notes explain the evidence consulted and its limits. Educational information does not replace individual medical care.

ME-PDQ

NCI: Melanoma treatment, patient PDQ

Melanocytes; cutaneous versus ocular disease; changing lesions; biopsy; stage; immunotherapy and targeted therapy · Supporting sections read on 11 November 2026 (UTC). Source verification is distinct from independent clinical appraisal.

Selected patient-education sections, not full current product labels or comparative treatment evidence. Numerical prognosis, universal BRAF eligibility and trial effect sizes are not adopted.

C-INF

NCI: Infection and neutropenia during cancer treatment

Infection signs; urgent contact; fever-masking medicines · Supporting sections read on 11 November 2026 (UTC). Source verification is distinct from independent clinical appraisal.

Older official safety education; individualized oncology emergency instructions take priority. No universal treatment schedule or infection-risk estimate adopted.

C-NUT

NCI: Nutrition during cancer treatment

Planning meals; effects on nutrition; individualized dietitian assessment · Supporting sections read on 11 November 2026 (UTC). Source verification is distinct from independent clinical appraisal.

Educational nutrition support, not evidence that a food treats cancer. No universal calorie, protein, supplement or fluid prescription adopted.

ME-NHS-SYM

NHS: Melanoma skin cancer symptoms

New or changing moles; when to seek help; observations of hard-to-see areas · Selected supporting text read on 11 November 2026 UTC. Educational context, not a diagnostic algorithm.

Diameter and image comparisons must not be used to rule out melanoma. No self-diagnosis or screening schedule adopted.

ME-NHS-DX

NHS: Tests and next steps for melanoma

Specialist examination; excision biopsy; next steps and support · Selected diagnosis and follow-up context read. Not individual clinical appraisal.

No universal timing guarantee for results or fixed personal testing pathway adopted.

ME-BRAF

NCI: Dabrafenib–trametinib combination and BRAF-positive tumors

Historical approval context; growth-promoting signals and BRAF V600E · Article mechanism and historical context read. Numerical results and cross-tumor efficacy not adopted.

Historical NCI report is not the current full prescribing label. No current exact eligibility, regimen or recommendation inferred.